Corium Announces Appointment of Ivan Gergel, M.D. to Board of Directors
GlobeNewswire - Mon Dec 08, 4:12PM CST
Corium International, Inc. (Nasdaq:CORI), a commercial-stage biopharmaceutical company focused on the development, manufacture and commercialization of specialty transdermal products, today announced the appointment of Ivan Gergel, M.D. to the Company's Board of Directors.
CORI: 5.86 (-0.06)
Corium concludes revised expanded term loan facility with CRG
M2 - Fri Dec 05, 4:27AM CST
Biopharmaceutical company Corium International (NasdaqGM:CORI) said on Thursday that it has completed its revised term loan facility with CRG and certain of its affiliate funds.
CORI: 5.86 (-0.06)
Corium Announces Closing of Expanded Term Loan Facility With CRG
GlobeNewswire - Thu Dec 04, 3:05PM CST
Corium International, Inc. (Nasdaq:CORI), a commercial-stage biopharmaceutical company focused on the development, manufacture and commercialization of specialty transdermal products, today announced that it has closed an expanded term loan facility with CRG and certain of its affiliate funds. The revised Term Loan Agreement provides an additional $10 million to the Company from CRG, which increases the aggregate principal loan amount to $45 million from the $35 million of outstanding principal provided for under the original agreement in July 2012. This revised term loan extends the maturity date of all debt to CRG from June 2017 to June 2019. Corium has drawn down the additional $10 million of principal available from this debt facility, primarily for use in supporting the advancement of its product development programs and proprietary technologies.
CORI: 5.86 (-0.06)
Corium International (CORI) Jumps: Stock Moves 14.3% Higher - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Nov 19, 8:25AM CST
Corium International (CORI) was a big mover last session, with shares rising over 14% on the day.
IPXL: 31.16 (-0.74), CORI: 5.86 (-0.06), AKRX: 41.24 (+0.38), MYL: 53.32 (-1.39)
Corium net loss improves in FY2014
Seeking Alpha - at Seeking Alpha - Tue Nov 18, 6:26AM CST
CORI: 5.86 (-0.06)
Corium beats by $0.01, misses on revenue
Seeking Alpha - at Seeking Alpha - Mon Nov 17, 3:15PM CST
CORI: 5.86 (-0.06)
Corium Reports Fiscal Year-End 2014 Financial Results and Recent Corporate Developments
GlobeNewswire - Mon Nov 17, 3:05PM CST
Corium International, Inc. (Nasdaq:CORI), a commercial-stage biopharmaceutical company focused on the development, manufacture and commercialization of specialty transdermal products, today announced unaudited financial results for the fiscal year ended September 30, 2014 and reported on recent corporate developments.
CORI: 5.86 (-0.06)
Corium to Report Fiscal Year-end 2014 Financial Results on Monday, November 17, 2014
GlobeNewswire - Tue Nov 11, 3:05PM CST
Corium International, Inc. (Nasdaq:CORI) today announced that it will report financial results for the fiscal year ended September 30, 2014 on Monday, November 17, 2014 after the close of the U.S. financial markets. Corium will host a conference call and live audio webcast at 5:00 p.m. Eastern time, 2:00 p.m. Pacific time to discuss its financial results.
CORI: 5.86 (-0.06)
Corium International (CORI) Jumps: Stock Adds 8.9% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Oct 22, 8:52AM CDT
Corium International (CORI) was a big mover last session, with shares rising nearly 9% on the day.
MNK: 94.72 (-0.36), LCI: 43.58 (-0.46), CORI: 5.86 (-0.06), CEMP: 19.00 (+0.47)
Leon Cooperman Picks Ocwen, Altisource Tumble
at The Street - Tue Oct 21, 2:30PM CDT
Corinthian Colleges Inc (NASDAQ:COCO), Gulf Coast Ultra Deep Royalty Trust – Royalty Trust Unit (NASDAQ:GULTU) and Corium International Inc (NASDAQ:CORI) are making notable climbs on the marke...
CORI: 5.86 (-0.06), ASPS: 49.25 (-0.47), OCN: 22.15 (-0.91), COCO: 0.09 (unch), GULTU: 1.04 (-0.06)
Corium Announces Appointment of Paul Goddard, Ph.D. to Board of Directors
GlobeNewswire - Wed Sep 17, 3:05PM CDT
Corium International, Inc. (Nasdaq:CORI), a commercial-stage biopharmaceutical company focused on the development, manufacture and commercialization of specialty transdermal products, today announced the appointment of Paul Goddard, Ph.D. to the Company's Board of Directors.
CORI: 5.86 (-0.06)
Should You Get Rid of Corium International (CORI) Now? - Tale of the Tape
Zacks Research Stuff - Zacks Investment Research - Wed Aug 20, 7:55AM CDT
Corium International stock could bring additional losses for your portfolio
MNK: 94.72 (-0.36), CORI: 5.86 (-0.06), AKRX: 41.24 (+0.38), SUPN: 8.72 (+0.02)
Corium Reports Third Fiscal Quarter 2014 Financial Results
GlobeNewswire - Tue Aug 12, 4:41PM CDT
Corium International, Inc. (Nasdaq:CORI), a commercial-stage biopharmaceutical company focused on the development, manufacture and commercialization of specialty transdermal products, today announced unaudited results from operations for both the third fiscal quarter and the nine months ended June 30, 2014. Corium's fiscal year ends on September 30, 2014.
CORI: 5.86 (-0.06)
Corium to Report Third Quarter Fiscal Year 2014 Financial Results on Tuesday, August 12, 2014
GlobeNewswire - Tue Aug 05, 3:09PM CDT
Corium International, Inc. (Nasdaq:CORI) today announced that it will release third quarter fiscal year 2014 financial results on Tuesday, August 12, 2014 after the close of the U.S. financial markets. Corium will host a conference call and live audio webcast at 5:00 p.m. Eastern time, 2:00 p.m. Pacific time to discuss its financial results.
CORI: 5.86 (-0.06)